Vericel Corporation

VCEL Healthcare Biotechnology

Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22.5%, EPS grew 500.0% and free cash flow grew 17,503.7%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

40.13 0.89 −2.17%
Market cap
$2.1B
P/E
83.6×
Fwd P/E
76.8×
Dividend yield
—
F-score
7/9
Altman Z
8.21
Beneish M
−2.53
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
92.69 74.81 112.53 121.04

+8 more quarters

P/S ratio
7.42 5.59 6.56 6.14
P/FCF ratio
36.85 34.40 73.25 77.98
P/Operating CF
140.35 99.70 120.74 71.95
P/B ratio
6.14 4.59 5.11 4.94
EV/Sales
6.94 5.15 6.13 5.68
EV/EBITDA
68.01 53.72 74.82 87.03
EV/FCF
34.50 31.70 68.39 72.18
Current Ratio
5.04 5.18 5.03 4.87
Net Debt/EBITDA
(40.05) 30.47 (5.37) (21.23)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
1.08% 1.34% 0.89% 0.83%
Free Cash Flow Yield
2.71% 2.91% 1.37% 1.28%
Free Cash Flow per Share
0.28 0.30 0.25 0.39
Book value per Share
7.25 7.02 7.04 6.37
Free Cash Flow
14.26 15.13 12.83 19.45
EV/EBIT
116.65 95.44 153.25 206.92
Other line items

Show all line items

Columns are period end dates